Hepatosplenic T cell lymphoma staging: Difference between revisions
(Created page with "{{Hepatosplenic T cell lymphoma}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Oncology [[Category:Gast...") |
(Mahshid) |
||
(4 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Hepatosplenic T cell lymphoma}} | {{Hepatosplenic T cell lymphoma}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | |||
According to the Lugano classification, there are four stages of hepatosplenic T cell lymphoma based on the number of nodes and extranodal involvement. | |||
==Staging== | |||
Staging for hepatosplenic T cell lymphoma is provided in the following table:<ref>{{Cite journal| doi = 10.1200/JCO.2013.54.8800| issn = 1527-7755| volume = 32| issue = 27| pages = 3059–3068| last1 = Cheson| first1 = Bruce D.| last2 = Fisher| first2 = Richard I.| last3 = Barrington| first3 = Sally F.| last4 = Cavalli| first4 = Franco| last5 = Schwartz| first5 = Lawrence H.| last6 = Zucca| first6 = Emanuele| last7 = Lister| first7 = T. Andrew| last8 = Alliance, Australasian Leukaemia and Lymphoma Group| last9 = Eastern Cooperative Oncology Group| last10 = European Mantle Cell Lymphoma Consortium| last11 = Italian Lymphoma Foundation| last12 = European Organisation for Research| last13 = Treatment of Cancer/Dutch Hemato-Oncology Group| last14 = Grupo Español de Médula Ósea| last15 = German High-Grade Lymphoma Study Group| last16 = German Hodgkin's Study Group| last17 = Japanese Lymphorra Study Group| last18 = Lymphoma Study Association| last19 = NCIC Clinical Trials Group| last20 = Nordic Lymphoma Study Group| last21 = Southwest Oncology Group| last22 = United Kingdom National Cancer Research Institute| title = Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification| journal = Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology| date = 2014-09-20| pmid = 25113753}}</ref> | |||
== | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
|+ '''Revised staging system for primary nodal lymphomas (Lugano classification)''' | |||
! style="background: #4479BA; color:#FFF;" | Stage | |||
! style="background: #4479BA; color:#FFF;" | Involvement | |||
! style="background: #4479BA; color:#FFF;" | Extranodal (E) status | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" colspan=3 | '''Limited''' | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" | I | |||
| style="padding: 5px 5px; background: #F5F5F5;" | One node or a group of adjacent nodes | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Single extranodal lesions without nodal involvement | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" | II | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Two or more nodal groups on the same side of the diaphragm | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Stage I or II by nodal extent with limited contiguous extranodal involvement | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" | II bulky* | |||
| style="padding: 5px 5px; background: #F5F5F5;" | II as above with "bulky" disease | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" colspan=3 | '''Advanced''' | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" | III | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" | IV | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Additional noncontiguous extralymphatic involvement | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Not applicable | |||
|} | |||
==References== | ==References== | ||
Line 9: | Line 43: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Hepatology]] |
Latest revision as of 02:02, 27 November 2017
Hepatosplenic T cell lymphoma Microchapters |
Differentiating Hepatosplenic T cell lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hepatosplenic T cell lymphoma staging On the Web |
American Roentgen Ray Society Images of Hepatosplenic T cell lymphoma staging |
Directions to Hospitals Treating Hepatosplenic T cell lymphoma |
Risk calculators and risk factors for Hepatosplenic T cell lymphoma staging |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
According to the Lugano classification, there are four stages of hepatosplenic T cell lymphoma based on the number of nodes and extranodal involvement.
Staging
Staging for hepatosplenic T cell lymphoma is provided in the following table:[1]
Stage | Involvement | Extranodal (E) status |
---|---|---|
Limited | ||
I | One node or a group of adjacent nodes | Single extranodal lesions without nodal involvement |
II | Two or more nodal groups on the same side of the diaphragm | Stage I or II by nodal extent with limited contiguous extranodal involvement |
II bulky* | II as above with "bulky" disease | Not applicable |
Advanced | ||
III | Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement | Not applicable |
IV | Additional noncontiguous extralymphatic involvement | Not applicable |
References
- ↑ Cheson, Bruce D.; Fisher, Richard I.; Barrington, Sally F.; Cavalli, Franco; Schwartz, Lawrence H.; Zucca, Emanuele; Lister, T. Andrew; Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute (2014-09-20). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. ISSN 1527-7755. PMID 25113753.